Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Dofetilide (compound)

Name: dofetilide
PubChem Compound ID: 71329
Molecular formula: C19H27N3O5S2
Molecular weight: 441.567 g/mol
Dofetilide [USAN:BAN:INN]; beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide; Tikosyn (TN); 115256-11-6; Dofetilida [INN-Spanish]; Xelide; UK-68798; Dofetilide (JAN/USAN); Dofetilidum [INN-Latin]; D00647.
show more »
Name: dofetilide
Name (isomeric): DB00204
Drug Type: small molecule
Dofetilida [INN-Spanish]; Dofetilidum [INN-Latin]
Brand: Dofetilida, Tikosyn
Category: Potassium Channel Blockers, Antiarrhythmic Agents, Anti-Arrhythmia Agents
CAS number: 115256-11-6
Indication: For the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
Dofetilide is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties and is indicated for the maintenance of normal sinus rhythm. Dofetilide increases the monophasic action potential duration in a predictable, concentration-dependent manner, primarily due to delayed repolarization. At concentrations covering...
show more »
Mechanism of Action:
The mechanism of action of Dofetilide is a blockade of the cardiac ion channel carrying the rapid component of the delayed rectifier potassium current, IKr. This inhibition of potassium channels results in a prolongation of action potential duration and the effective refractory period of accessory pathways (both anterograde and retrograde conductio...
show more »
Absorption: >90%
Protein binding: 60% -70%
Biotransformation: Hepatic
Half Life: 10 hours
Affected organisms: Humans and other mammals
Drug interaction:
ErythromycinIncreased risk of cardiotoxicity and arrhythmias
TelithromycinIncreased risk of cardiotoxicity and arrhythmias
VerapamilVerapamil may increase the plamsa levels of Dofetilide. Increased risk of torsade de pointes. Concomitant therapy is contraindicated.
CimetidineIncreases effect/toxicity of dofetilide
ZuclopenthixolAdditive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
show more »